The Lens on LEN: Advocates’ Primer and More on lenavapavir
View this email in your browser ([link removed])
[link removed] July 8, 2024
** Advocates’ Primer on lenacapavir for PrEP
------------------------------------------------------------
Dear Advocate,
Late last month, we learned of the exciting interim result of the PURPOSE 1 HIV prevention study ([link removed]) of injectable lenacapavir (LEN) for HIV prevention among cisgender women and adolescent girls after an independent monitoring board found it to be safe and highly effective against HIV. AVAC issued a statement ([link removed]) calling for early planning to accelerate its regulatory review and for ambitious introduction plans, and the PURPOSE 1 Global Community Accountability Group (GCAG) and the African Women’s Prevention Community Accountability Board also issued a statement
([link removed]) celebrating the crucial role of African women and communities in this study.
Today, AVAC, the GCAG ([link removed]) and the Accountability Board ([link removed]) are joined by the Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting PrEP ([link removed]) , and the Coalition to Accelerate and Support Prevention Research (CASPR) ([link removed]) in issuing a further call to action ([link removed]) , with specific priorities about what needs to happen next.
In addition, AVAC is releasing the Lens on LEN: The basics on injectable lenacapavir as PrEP ([link removed]) . This Advocates’ Primer provides background on the product and trials; a summary of the early findings of PURPOSE 1; key remaining questions; and critical next steps.
Read on for more about these resources.
PRIMER
[link removed]
** The Lens on LEN: The basics on injectable lenacapavir as PrEP
------------------------------------------------------------
Re ([link removed]) ad more [link removed]
Call to action
** Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Twice-Yearly Injectable Lenacapavir for PrEP
------------------------------------------------------------
In this call to action, the PURPOSE 1 Global Community Accountability Board (GCAG), the Civil Society Caucus of the long-acting PrEP Coalition, the African Women Community Prevention Accountability Board, and the Coalition to Accelerate and Support Prevention Research (CASPR) call on all stakeholders to urgently come together to learn the lessons of past PrEP product introduction and apply them to compress the timeline for making this important new option to become widely available to those who need and want to use it.
r ([link removed]) ead more
article
[link removed]
** New Drug Provides Total Protection From H.I.V. in Trial of Young African Women ([link removed])
------------------------------------------------------------
This New York Times ([link removed]) article provides terrific perspectives from AVAC partners Linda-Gail Bekker, Yvette Raphael and Lillian Mworeko. “For a young woman who can’t get to an appointment at a clinic in a town, a young woman who can’t keep pills without facing stigma or violence — an injection just twice a year is the option that could keep her free of HIV,” said Lillian Mworeko, who leads a group called the International Community of Women Living With HIV Eastern Africa.
r ([link removed]) ead more
We hope this new primer and our joint call to action are helpful in our collective advocacy to translate these exciting clinical trial results into actual public health impact with speed, scale and equity.
Best,
AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423
[email protected] (mailto:
[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
